Author: "Loo, M." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Loo, M."' showing total 764 results

Start Over Author "Loo, M."

764 results on '"Loo, M."'

1. Chronic fatigue in childhood cancer survivors is associated with lifestyle and psychosocial factors; a DCCSS LATER study

Author: Penson, A., Walraven, I., Bronkhorst, E., Grootenhuis, M.A., Maurice-Stam, H., de Beijer, I., van der Heiden-van der Loo, M., Tissing, W.J.E., van der Pal, H.J.H., de Vries, A.C.H., Bresters, D., Ronckers, C.M., van den Heuvel-Eibrink, M.M., Neggers, S., Versluys, B.A.B., Louwerens, M., Pluijm, S.M.F., Blijlevens, N., van Dulmen-den Broeder, E., Kremer, L.C.M., Knoop, H., and Loonen, J.
Published: 2023
Full Text: View/download PDF

2. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

Author: Abela, I., Aebi-Popp, K., Anagnostopoulos, A., Battegay, M., Bernasconi, E., Braun, D.L., Bucher, H.C., Calmy, A., Cavassini, M., Ciuffi, A., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, C.A., Günthard, H.F., Hachfeld, A., Haerry, D., Hasse, B., Hirsch, H.H., Hoffmann, M., Hösli, I., Huber, M., Jackson-Perry, D., Kahlert, C.R., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R.D., Kovari, H., Kusejko, K., Labhardt, N., Leuzinger, K., de Tejada B, Martinez, Marzolini, C., Metzner, K.J., Müller, N., Nemeth, J., Nicca, D., Notter, J., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Salazar-Vizcaya, L., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weisser, M., Yerly, S., van der Valk, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lempkes, B., Nellen, F.J.B., van der Poll, T., Prins, J.M., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Wit, F.W.M.N., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., van Hes, A.M.H., Pijnappel, F.J.J., Smalhout, S.Y., Weijsenfeld, A.M., Back, N.K.T., Berkhout, B., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Wolthers, K.C., Zaaijer, H.L., Peters, E.J.G., van Agtmael, M.A., Autar, R.S., Bomers, M., Sigaloff, K.C.E., Heitmuller, M., Laan, L.M., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Munnik, E.S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., van Eeden, A., Hoornenborg, E., Nellen, J., Alers, W., Elsenburg, L.J.M., Nobel, H., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Rijkevoorsel, M. Pawels-van, Buiting, A.G.M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Duijf-van de Ven, C.J.H.M., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van Winden, S., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., van der Bliek, G.L., Bor, P.C.J., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., Dorama, W., van Holten, N., Claas, E.C.J., Wessels, E., Hollander, J.G. den, El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Lashof, A.M.L. Oude, Posthouwer, D., van Wolfswinkel, M.E., Ackens, R.P., Burgers, K., Elasri, M., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., van Broekhuizen, M.C., S, Faber, Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., van Truijen-Oud, F.A., Stuart, J.W.T. Cohen, Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Veenstra, J., Vrouenraets, S.M.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., Hofstede, H.J.M. ter, Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., Beest, G. ter, van Bentum, P.H.M., Gelling, M., Neijland, Y., Swanink, C.M.A., Velderman, M. Klein, van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., de Jonge, H., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., T.Mudrikova, Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., van Welzen, B.J., Berends, H., Santen, B.M.G. Griffioen-van, de Kroon, I., Lunel, F.M. Verduyn, Wensing, A.M.J., Zaheri, S., Boyd, A.C., Bezemer, D.O., van Sighem, A.I., Smit, C., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Lelivelt, K.J., van de Sande, L., van der Vliet, K.M. Visser.S.T., Paling, F., de Groot-Berndsen, L.G.M., van den Akker, M., Alexander, R., Bakker, Y., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Groters, M., Koster, L.E., Lodewijk, C.R.E., Lucas, E.G.A., Munjishvili, L., Peeck, B.M., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., Schoorl, M.J.C., Tuijn, E.M., Veenenberg, D.P., Witte, E.C.M., Bretin, N.M., Karpov, I., Losso, M., Lundgren, J., Rockstroh, J., Aho, I., Rasmussen, L.D., Novak, P., Pradier, C., Chkhartishvili, N., Matulionyte, R., Oprea, C., Kowalska, J.D., Begovac, J., Miró, J.M., Guaraldi, G., Paredes, R., Peters, L., Larsen, J.F., Neesgaard, B., Jaschinski, N., Fursa, O., Raben, D., Kristensen, D., Fischer, A.H., Jensen, S.K., Elsing, T.W., Gardizi, M., Mocroft, A., Phillips, A., Reekie, J., Cozzi-Lepri, A., Pelchen-Matthews, A., Roen, A., Tusch, E.S., Bannister, W., Bellecave, P., Blanco, P., Bonnet, F., Bouchet, S., Breilh, D., Cazanave, C., Desjardin, S., Gaborieau, V., Gimbert, A., Hessamfar, M., Lacaze-Buzy, L., Lacoste, D., Lafon, M.E., Lazaro, E., Leleux, O., Le Marec, F., Le Moal, G., Malvy, D., Marchand, L., Mercié, P., Neau, D., Pellegrin, I., Perrier, A., Petrov-Sanchez, V., Vareil, M.O., Wittkop, L., Bernard, N., Chaussade, D. Bronnimann H., Dondia, D., Duffau, P., Faure, I., Morlat, P., Mériglier, E., Paccalin, F., Riebero, E., Rivoisy, C., Vandenhende, M.A., Barthod, L., Dauchy, F.A., Desclaux, A., Ducours, M., Dutronc, H., Duvignaud, A., Leitao, J., Lescure, M., Nguyen, D., Pistone, T., Puges, M., Wirth, G., Courtault, C., Camou, F., Greib, C., Pellegrin, J.L., Rivière, E., Viallard, J.F., Imbert, Y., Thierry-Mieg, M., Rispal, P., Caubet, O., Ferrand, H., Tchamgoué, S., Farbos, S., Wille, H., Andre, K., Caunegre, L., Gerard, Y., Osorio-Perez, F., Chossat, I., Iles, G., Labasse-Depis, M., Lacassin, F., Barret, A., Castan, B., Koffi, J., Rouanes, N., Saunier, A., Zabbe, J.B., Dumondin, G., Beraud, G., Catroux, M., Garcia, M., Giraud, V., Martellosio, J.P., Roblot, F., Pasdeloup, T., Riché, A., Grosset, M., Males, S., Bell, C. Ngo, Carpentier, C., Bellecave, Virology P., Tumiotto, C., Miremeont-Salamé, G., Arma, D., Arnou, G., Blaizeau, M.J., Camps, P., Decoin, M., Delveaux, S., Diarra, F., Gabrea, L., Lawson-Ayayi, S., Lenaud, E., Plainchamps, D., Pougetoux, A., Uwamaliya, B., Zara, K., Conte, V., Gapillout, M., Surial, Bernard, Ramírez Mena, Adrià, Roumet, Marie, Limacher, Andreas, Smit, Colette, Leleux, Olivier, Mocroft, Amanda, van der Valk, Marc, Bonnet, Fabrice, Peters, Lars, Rockstroh, Jürgen K., Günthard, Huldrych F., Berzigotti, Annalisa, Rauch, Andri, and Wandeler, Gilles
Published: 2023
Full Text: View/download PDF

3. Support needs of Dutch young adult childhood cancer survivors

Author: van Erp, L. M. E., Maurice-Stam, H., Kremer, L. C. M., Tissing, W. J. E., van der Pal, H. J. H., Beek, L., de Vries, A. C. H., van den Heuvel-Eibrink, M. M., Versluys, B. A. B., van der Heiden-van der Loo, M., van Gorp, M., Huizinga, G. A., and Grootenhuis, M. A.
Published: 2022
Full Text: View/download PDF

4. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study

Author: Oomen, Patrick G A, Wit, Ferdinand W N M, Brinkman, Kees, Vrouenraets, Saskia M E, Mudrikova, Tania, van Welzen, Berend J, van der Valk, Marc, van Agtmael, M.A., Bomers, M., Geerlings, S.E., Goorhuis, A., Harris, V.C., Hovius, J.W., Lemkes, B., Nellen, F.J.B., Peters, E.J.G., van der Poll, T., Prins, J.M., Sigaloff, K.C.E., Spoorenberg, V., van Vugt, M., Wiersinga, W.J., Bruins, C., van Eden, J., Hylkema-van den Bout, I.J., Laan, L.M., Pijnappel, F.J.J., Smalhout, S.Y., Spelbrink, M.E., Weijsenfeld, A.M., Back, N.K.T., Cornelissen, M.T.E., van Houdt, R., Jonges, M., Jurriaans, S., Schinkel, C.J., Welkers, M.R.A., Wolthers, K.C., van den Berge, M., Stegeman, A., Baas, S., Hage de Looff, L., van Arkel, A., Stohr, J., Wintermans, B., Pronk, M.J.H., Ammerlaan, H.S.M., de Bree, C., de Munnik, E.S., Phaf, S., Deiman, B., Jansz, A.R., Scharnhorst, V., Tjhie, J., Wegdam, M.C.A., Nellen, J., van Eeden, A., Hoornenborg, E., de Stoppelaar, S., Alers, W., Elsenburg, L.J.M., Nobel, H., Schinkel, C.J., van Kasteren, M.E.E., Berrevoets, M.A.H., Brouwer, A.E., de Kruijf-van de Wiel, B.A.F.M., Adams, A., Pawels-van Rijkevoorsel, M., Murck, J.L., Rokx, C., Anas, A.A., Bax, H.I., van Gorp, E.C.M., de Mendonça Melo, M., van Nood, E., Nouwen, J.L., Rijnders, B.J.A., Schurink, C.A.M., Slobbe, L., de Vries-Sluijs, T.E.M.S., Bassant, N., van Beek, J.E.A., Vriesde, M., van Zonneveld, L.M., de Groot, J., van Kampen, J.J.A., Koopmans, M.P.G., Rahamat-Langendoen, J.C., Branger, J., Douma, R.A., Cents-Bosma, A.S., Mulder, M.A., Schippers, E.F., van Nieuwkoop, C., Geilings, J., van de Ven, E., van der Hut, G., van Burgel, N.D., Leyten, E.M.S., Gelinck, L.B.S., Mollema, F., Langbein, M., Wildenbeest, G.S., Nguyen, T., Groeneveld, P.H.P., Bouwhuis, J.W., Lammers, A.J.J., van Hulzen, A.G.W., Kraan, S., Kruiper, M.S.M., Debast, S.B., Wagenvoort, G.H.J., Roukens, A.H.E., de Boer, M.G.J., Jolink, H., Lambregts, M.M.C., Scheper, H., van Holten, N., van der Sluis, D., Claas, E.C.J., Wessels, E., den Hollander, J.G., El Moussaoui, R., Pogany, K., Brouwer, C.J., Heida-Peters, D., Mulder, E., Smit, J.V., Struik-Kalkman, D., van Niekerk, T., Pontesilli, O., van Tienen, C., Lowe, S.H., Oude Lashof, A.M.L., Posthouwer, D., Stoop, A., van Wolfswinkel, M.E., Ackens, R.P., Elasri, M., Houben-Pintaric, K., Schippers, J., Havenith, T.R.A., van Loo, M., van Vonderen, M.G.A., Kampschreur, L.M., Timmer, C., van Broekhuizen, M.C., Faber, S., Al Moujahid, A., Kootstra, G.J., Delsing, C.E., van der Burg-van de Plas, M., Scheiberlich, L., Kortmann, W., van Twillert, G., Renckens, R., Wagenaar, J., Ruiter-Pronk, D., Stander, B., Cohen Stuart, J.W.T., Hoogewerf, M., Rozemeijer, W., Sinnige, J.C., Brinkman, K., van den Berk, G.E.L., Lettinga, K.D., de Regt, M., Schouten, W.E.M., Stalenhoef, J.E., Blaauw, H., Geerders, G.F., Kleene, M.J., Knapen, M., Kok, M., van der Meché, I.B., Toonen, A.J.M., Wijnands, S., Wttewaal, E., Kwa, D., van de Laar, T.J.W., van Crevel, R., van Aerde, K., Dofferhoff, A.S.M., Henriet, S.S.V., ter Hofstede, H.J.M., Hoogerwerf, J., Richel, O., Albers, M., Grintjes-Huisman, K.J.T., de Haan, M., Marneef, M., McCall, M., Rahamat-Langendoen, J., Ruizendaal, E., Burger, D., Gisolf, E.H., Claassen, M., Hassing, R.J., ter Beest, G., van Bentum, P.H.M., Neijland, Y., Valette, M., Swanink, C.M.A., Klein Velderman, M., van Lelyveld, S.F.L., Soetekouw, R., van der Prijt, L.M.M., van der Swaluw, J., Kalpoe, J.S., Wagemakers, A., Vahidnia, A., Lauw, F.N., Verhagen, D.W.M., van Wijk, M., Bierman, W.F.W., Bakker, M., van Bentum, R.A., van den Boomgaard, M.A., Kleinnijenhuis, J., Kloeze, E., Middel, A., Postma, D.F., Schenk, H.M., Stienstra, Y., Wouthuyzen-Bakker, M., Boonstra, A., Maerman, M.M.M., de Weerd, D.A., van Eije, K.J., Knoester, M., van Leer-Buter, C.C., Niesters, H.G.M., Barth, R.E., Bruns, A.H.W., Ellerbroek, P.M., Hensgens, M.P.M., Oosterheert, J.J., Schadd, E.M., Verbon, A., Griffioen-van Santen, B.M.G., de Kroon, I., Schuurman, R., Verduyn Lunel, F.M., Wensing, A.M.J., van der Valk, M., Zaheri, S., Boyd, A.C., Bezemer, D.O., Jongen, V.W., van Sighem, A.I., Smit, C., Wit, F.W.M.N., Hillebregt, M.M.J., Woudstra, T.J., Rutkens, T., Bergsma, D., Brétin, N.M., Koster, L.E., Lelivelt, K.J., van de Sande, L., Schoorl, M.J.C., Visser, K.M., van der Vliet, S.T., Paling, F., van den Akker, M., Akpomukai, O.M., Alexander, R., Bakker, Y.M., Bastos Sales, L., El Berkaoui, A., Bezemer-Goedhart, M., Djoechro, E.A., Grolleman, J.M., El Hammoud, I., Khouw, M.R., Lodewijk, C.R.E., Lucas, E.G.A., van Meerveld-Derks, S., Mulder, H.W., Munjishvili, L., Ree, C.M.J., Regtop, R., van Rijk, A.F., Ruijs-Tiggelman, Y.M.C., Schnörr, P.P., van Veen, R., van Vliet-Klein Gunnewiek, W.H.G., and Witte, E.C.M.
Abstract: Currently, real-world data on doravirine are scarce. In a national prospective cohort, we assessed the effectiveness and tolerability of switching to doravirine-based antiretroviral therapy (ART) in people with HIV.
Published: 2024
Full Text: View/download PDF

5. A vulnerable age group: the impact of cancer on the psychosocial well-being of young adult childhood cancer survivors

Author: van Erp, L. M. E., Maurice-Stam, H., Kremer, L. C. M., Tissing, W. J. E., van der Pal, H. J. H., de Vries, A. C. H., van den Heuvel-Eibrink, M. M., Versluys, B. A. B., van der Heiden-van der Loo, M., Huizinga, G. A., and Grootenhuis, M. A.
Published: 2021
Full Text: View/download PDF

6. Prozessevaluation eines interaktiven webbasierten Schubmanagement-Programms für Menschen mit Multipler Sklerose (POWER@MS2) - Mixed-methods-Studie

Author: Bremer, L, Peper, J, Wenzel, L, Scheiderbauer, J, van de Loo, M, Heesen, C, Köpke, S, Rahn, AC, Bremer, L, Peper, J, Wenzel, L, Scheiderbauer, J, van de Loo, M, Heesen, C, Köpke, S, and Rahn, AC
Published: 2024

7. Begleitende Mixed-Methods-Prozessevaluation eines Schubmanagement-Programms für Menschen mit Multipler Sklerose (POWER@MS2)

Author: Bremer, L, Peper, J, Wenzel, L, Scheiderbauer, J, Van de Loo, M, Heesen, C, Köpke, S, Rahn, AC, Bremer, L, Peper, J, Wenzel, L, Scheiderbauer, J, Van de Loo, M, Heesen, C, Köpke, S, and Rahn, AC
Published: 2024

8. Prevalence, risk factors and optimal way to determine overweight, obesity and morbid obesity, in the first Dutch cohort of 2,338 long-term survivors of childhood cancer: a DCCSS-LATER study

Author: Pluimakers, V G, primary, van Atteveld, J E, additional, de Winter, D T C, additional, Bolier, M, additional, Fiocco, M, additional, Nievelstein, R A J, additional, Janssens, G O R, additional, Bresters, D, additional, van der Heiden-van der Loo, M, additional, de Vries, A C H, additional, Louwerens, M, additional, van der Pal, H J, additional, Pluijm, S M F, additional, Ronckers, C M, additional, Versluijs, A B, additional, Kremer, L C M, additional, Loonen, J J, additional, van Dulmen-den Broeder, E, additional, Tissing, W J E, additional, van Santen, H M, additional, van den Heuvel-Eibrink, M M, additional, and Neggers, S J C M M, additional
Published: 2023
Full Text: View/download PDF

9. Desire for children among male survivors of childhood cancer

Author: Claessens, J.J.M., Penson, A., Bronkhorst, E.M., Kremer, L.C.M., Dulmen-den Broeder, E. van, Heiden-van der Loo, M., Tissing, W.J.E., Pal, H.J. van der, Blijlevens, N.M.A., Heuvel-Eibrink, M.M. van den, Versluys, A.B., Bresters, D., Ronckers, C.M., Walraven, I., Beerendonk, C.C., Loonen, J.J., Pediatrics, CCA - Cancer Treatment and quality of life, and Amsterdam Reproduction & Development (AR&D)
Subjects: Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Cancer Research, All institutes and research themes of the Radboud University Medical Center, Oncology, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract: Contains fulltext : 291886.pdf (Publisher’s version ) (Open Access) BACKGROUND: Knowledge of the desire for children among childhood cancer survivors (CCSs) is scarce. This study evaluated the desire for children in male CCSs in comparison with male siblings. METHODS: A nationwide cohort study was conducted as part of the Dutch Childhood Cancer Survivor Study LATER study: 1317 male CCSs and 407 male sibling controls completed a questionnaire addressing the desire for children. Logistic regression analyses were used to explore the independent association between survivorship status and the desire for children. Furthermore, additional analyses were performed to identify which cancer-related factors were associated with the desire for children in male CCSs. RESULTS: After adjustments for the age at assessment, the percentage of men who had a desire for children was significantly lower among CCSs compared with the siblings (74% vs. 82%; odds ratio [OR], 0.61; 95% CI, 0.46-0.82; p = .001). The association between survivorship status and the desire for children was attenuated after adjustments for marital status, level of education, and employment status (OR, 0.83; 95% CI, 0.61-1.14; p = .250). The percentage of men who had an unfulfilled desire for children remained significantly higher among CCSs compared with the siblings after adjustments for sociodemographic factors (25% vs. 7%; OR, 5.14; 95% CI, 2.48-10.64; p
Published: 2023

10. Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER)

Author: Atteveld, Jenneke van, Winter, D.T.C. de, Pluimakers, V.G., Fiocco, M., Nievelstein, R.A., Hobbelink, M.G., Kremer, L.C.M., Grootenhuis, M.A., Maurice-Stam, H., Tissing, W.J.E., Vries, A.C.M. de, Loonen, J.J., Dulmen-den Broeder, E. van, Pal, H.J. van der, Pluijm, S.M.F., Heiden-van der Loo, M., Versluijs, A.B., Louwerens, M., Bresters, D., Santen, H.M. van, Hoefer, I., Berg, S.A. van den, Hartogh, J. den, Hoeijmakers, J.H.J., Neggers, S.J., Heuvel-Eibrink, M.M. van den, Pediatrics, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), Clinical Chemistry, Internal Medicine, and Molecular Genetics
Subjects: Psychiatry and Mental health, All institutes and research themes of the Radboud University Medical Center, Health (social science), SDG 3 - Good Health and Well-being, Geriatrics and Gerontology, Family Practice, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract: Contains fulltext : 291552.pdf (Publisher’s version ) (Open Access) BACKGROUND: Childhood cancer survivors appear to be at increased risk of frailty and sarcopenia, but evidence on the occurrence of and high-risk groups for these aging phenotypes is scarce, especially in European survivors. The aim of this cross-sectional study was to assess the prevalence of and explore risk factors for pre-frailty, frailty, and sarcopenia in a national cohort of Dutch childhood cancer survivors diagnosed between 1963 and 2001. METHODS: Eligible individuals (alive at the time of study, living in the Netherlands, age 18-45 years, and had not previously declined to participate in a late-effects study) from the Dutch Childhood Cancer Survivor Study (DCCSS-LATER) cohort were invited to take part in this cross-sectional study. We defined pre-frailty and frailty according to modified Fried criteria, and sarcopenia according to the European Working Group on Sarcopenia in Older People 2 definition. Associations between these conditions and demographic and treatment-related as well as endocrine and lifestyle-related factors were estimated with two separate multivariable logistic regression models in survivors with any frailty measurement or complete sarcopenia measurements. FINDINGS: 3996 adult survivors of the DCCSS-LATER cohort were invited to participate in this cross-sectional study. 1993 non-participants were excluded due to lack of response or a decline to participate and 2003 (50·1%) childhood cancer survivors aged 18-45 years were included. 1114 (55·6%) participants had complete frailty measurements and 1472 (73·5%) participants had complete sarcopenia measurements. Mean age at participation was 33·1 years (SD 7·2). 1037 (51·8%) participants were male, 966 (48·2%) were female, and none were transgender. In survivors with complete frailty measurements or complete sarcopenia measurements, the percentage of pre-frailty was 20·3% (95% CI 18·0-22·7), frailty was 7·4% (6·0-9·0), and sarcopenia was 4·4% (3·5-5·6). In the models for pre-frailty, underweight (odds ratio [OR] 3·38 [95% CI 1·92-5·95]) and obesity (OR 1·67 [1·14-2·43]), cranial irradiation (OR 2·07 [1·47-2·93]), total body irradiation (OR 3·17 [1·77-5·70]), cisplatin dose of at least 600 mg/m(2) (OR 3·75 [1·82-7·74]), growth hormone deficiency (OR 2·25 [1·23-4·09]), hyperthyroidism (OR 3·72 [1·63-8·47]), bone mineral density (Z score ≤-1 and >-2, OR 1·80 [95% CI 1·31-2·47]; Z score ≤-2, OR 3·37 [2·20-5·15]), and folic acid deficiency (OR 1·87 [1·31-2·68]) were considered significant. For frailty, associated factors included age at diagnosis between 10-18 years (OR 1·94 [95% CI 1·19-3·16]), underweight (OR 3·09 [1·42-6·69]), cranial irradiation (OR 2·65 [1·59-4·34]), total body irradiation (OR 3·28 [1·48-7·28]), cisplatin dose of at least 600 mg/m(2) (OR 3·93 [1·45-10·67]), higher carboplatin doses (per g/m(2); OR 1·15 [1·02-1·31]), cyclophosphamide equivalent dose of at least 20 g/m(2) (OR 3·90 [1·65-9·24]), hyperthyroidism (OR 2·87 [1·06-7·76]), bone mineral density Z score ≤-2 (OR 2·85 [1·54-5·29]), and folic acid deficiency (OR 2·04 [1·20-3·46]). Male sex (OR 4·56 [95%CI 2·26-9·17]), lower BMI (continuous, OR 0·52 [0·45-0·60]), cranial irradiation (OR 3·87 [1·80-8·31]), total body irradiation (OR 4·52 [1·67-12·20]), hypogonadism (OR 3·96 [1·40-11·18]), growth hormone deficiency (OR 4·66 [1·44-15·15]), and vitamin B12 deficiency (OR 6·26 [2·17-1·81]) were significantly associated with sarcopenia. INTERPRETATION: Our findings show that frailty and sarcopenia occur already at a mean age of 33 years in childhood cancer survivors. Early recognition and interventions for endocrine disorders and dietary deficiencies could be important in minimising the risk of pre-frailty, frailty, and sarcopenia in this population. FUNDING: Children Cancer-free Foundation, KiKaRoW, Dutch Cancer Society, ODAS Foundation. 01 april 2023
Published: 2023

11. Pulmonary interstitial glycogenosis – A systematic analysis of new cases

Author: Seidl, E., Carlens, J., Reu, S., Wetzke, M., Ley-Zaporozhan, J., Brasch, F., Wesselak, T., Schams, A., Rauch, D., Schuch, L., Kappler, M., Schelstraete, P., Wolf, M., Stehling, F., Haarmann, E., Borensztajn, D., van de Loo, M., Rubak, S., Lex, C., Hinrichs, B., Reiter, K., Schwerk, N., and Griese, M.
Published: 2018
Full Text: View/download PDF

12. Psychosocial functioning of parents of Dutch long-term survivors of childhood cancer

Author: Gorp, M. van, Joosten, M.M.H., Maas, A., Drenth, B.L., Aa-van Delden, A. van der, Kremer, L.C.M., Dulmen-den Broeder, E. van, Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Ronckers, C., Bresters, D., Louwerens, M., Neggers, S.J.C.C.M., Heiden-van der Loo, M. van der, Maurice-Stam, H., Grootenhuis, M.A., Dutch LATER Study Grp, Pediatrics, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Paediatric Oncology, Paediatric Pulmonology, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Child and Adolescent Psychiatry & Psychosocial Care, CCA - Cancer Treatment and quality of life, and Amsterdam Reproduction & Development (AR&D)
Subjects: parents, Experimental and Cognitive Psychology, survivors of childhood cancer, pediatric oncology, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], health-related quality of life, Psychiatry and Mental health, All institutes and research themes of the Radboud University Medical Center, Oncology, SDG 3 - Good Health and Well-being, psychosocial outcomes, illness cognitions, post-traumatic growth, psycho-oncology, post-traumatic stress
Abstract: Contains fulltext : 291391.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To describe health-related quality of life (HRQoL), post-traumatic stress and post-traumatic growth of parents of long-term survivors of childhood cancer (CCS) and study associated factors. METHODS: Parents of survivors of the Dutch Childhood Cancer Survivor Study LATER cohort below 30 years and diagnosed 1986-2001 were invited to complete the TNO-AZL Questionnaire for Adult's HRQoL (e.g., sleep and aggressive emotions), Self-Rating Scale for Post-traumatic Stress Disorder, Post-traumatic Growth Inventory, and Illness Cognition Questionnaire. HRQoL domain scores were compared to references using Mann-Whitney U tests. Correlations between post-traumatic stress, growth and HRQoL were evaluated. Medical characteristics of their child and illness cognitions were studied as associated factors of HRQOL, post-traumatic stress and growth. p
Published: 2023

13. Site of childhood cancer care in the Netherlands

Author: Reedijk, A.M.J., van der Heiden-van der Loo, M., Visser, O., Karim-Kos, H.E., Lieverst, J.A., de Ridder-Sluiter, J.G., Coebergh, J.W.W., Kremer, L.C., and Pieters, R.
Published: 2017
Full Text: View/download PDF

14. Lactate and hyperlactatemia revisited: an overview

Author: Van Loo, M, primary, Iturriagagoitia, X, additional, Van Limmen, J, additional, Vandenheuvel, M, additional, and De Hert, S, additional
Published: 2023
Full Text: View/download PDF

15. Adverse late health outcomes among children treated with 3D radiotherapy techniques: Study design of the Dutch pediatric 3D-RT study.

Author: Beijer, J.G.M., Kok, J.L., Janssens, G.O., Streefkerk, N., Vries, A.C.M. de, Slagter, C., Maduro, J.H., Kroon, P.S., Grootenhuis, M.A., Dulmen-den Broeder, E. van, Loonen, J.J., Wendling, M., Tissing, W.J.E., Pal, H.J. van der, Louwerens, M., Bel, A., Hartogh, J. den, Heiden-van der Loo, M., Kremer, L.C.M., Teepen, J.C., Ronckers, C.M., Beijer, J.G.M., Kok, J.L., Janssens, G.O., Streefkerk, N., Vries, A.C.M. de, Slagter, C., Maduro, J.H., Kroon, P.S., Grootenhuis, M.A., Dulmen-den Broeder, E. van, Loonen, J.J., Wendling, M., Tissing, W.J.E., Pal, H.J. van der, Louwerens, M., Bel, A., Hartogh, J. den, Heiden-van der Loo, M., Kremer, L.C.M., Teepen, J.C., and Ronckers, C.M.
Abstract: 01 februari 2023, Item does not contain fulltext, BACKGROUND: Adverse late health outcomes after multimodal treatment for pediatric cancer are diverse and of prime interest. Currently available evidence and survivorship care guidelines are largely based on studies addressing side-effects of two dimensional planned radiotherapy. AIMS: The Dutch pediatric 3D-planned radiotherapy (3D-RT) study aims to gain insight in the long-term health outcomes among children who had radiotherapy in the 3D era. Here, we describe the study design, data-collection methods, and baseline cohort characteristics. METHODS AND RESULTS: The 3D-RT study represents an expansion of the Dutch Childhood Cancer Survivor study (DCCSS) LATER cohort, including pediatric cancer patients diagnosed during 2000-2012, who survived at least 5 years after initial diagnosis and 2 years post external beam radiotherapy. Individual cancer treatment parameters were obtained from medical files. A national infrastructure for uniform collection and archival of digital radiotherapy files (Computed Tomography [CT]-scans, delineations, plan, and dose files) was established. Health outcome information, including subsequent tumors, originated from medical records at the LATER outpatient clinics, and national registry-linkage. With a median follow-up of 10.9 (interquartile range [IQR]: 7.9-14.3) years after childhood cancer diagnosis, 711 eligible survivors were identified. The most common cancer types were Hodgkin lymphoma, medulloblastoma, and nephroblastoma. Most survivors received radiotherapy directed to the head/cranium only, the craniospinal axis, or the abdominopelvic region. CONCLUSION: The 3D-RT study will provide knowledge on the risk of adverse late health outcomes and radiation-associated dose-effect relationships. This information is valuable to guide follow-up care of childhood cancer survivors and to refine future treatment protocols.
Published: 2023

16. Self-reported outcomes on oral health and oral health-related quality of life in long-term childhood cancer survivors-A DCCSS-LATER 2 Study.

Author: Stolze, J., Raber-Durlacher, J.E., Loonen, J.J., Teepen, J.C., Ronckers, C.M., Tissing, W.J.E., Vries, A.C.M. de, Neggers, S.J., men-den Broeder, E. Dul, Heuvel-Eibrink, M.M. van den, Pal, H.J. van der, Versluys, A.B., van der Loo, M. Heiden, Louwerens, M., Kremer, L.C.M., Bresters, D., Brand, H.S., Stolze, J., Raber-Durlacher, J.E., Loonen, J.J., Teepen, J.C., Ronckers, C.M., Tissing, W.J.E., Vries, A.C.M. de, Neggers, S.J., men-den Broeder, E. Dul, Heuvel-Eibrink, M.M. van den, Pal, H.J. van der, Versluys, A.B., van der Loo, M. Heiden, Louwerens, M., Kremer, L.C.M., Bresters, D., and Brand, H.S.
Abstract: Contains fulltext : 293041.pdf (Publisher’s version ) (Open Access), PURPOSE: The present study aimed to determine the prevalence of self-reported oral problems and the oral health-related quality of life (OHRQoL) in childhood cancer survivors (CCS). METHODS: Patient and treatment characteristics of CCS have been collected in a cross-sectional study, part of the multidisciplinary DCCSS-LATER 2 Study. To assess self-reported oral health problems and dental problems, CCS filled out the 'Toegepast-Natuurwetenschappelijk Onderzoek' (TNO) oral health questionnaire. OHRQoL was assessed by the Dutch version of the Oral Health Impact Profile-14 (OHIP-14). Prevalences were compared with two comparison groups from the literature. Univariable and multivariable analyses were performed. RESULTS: A total of 249 CCS participated in our study. The OHIP-14 total score had a mean value of 1.94 (sd 4.39), with a median score of 0 (range 0-29). The oral problems 'oral blisters/aphthae' (25.9%) and 'bad odor/halitosis' (23.3%) were significantly more often reported in CCS than in comparison groups (12% and 12%, respectively). The OHIP-14 score was significantly correlated with the number of self-reported oral health problems (r = .333, p<0.0005) and dental problems (r = .392, p <0.0005). In multivariable analysis, CCS with a shorter time since diagnosis (10-19 years vs. ≥30 years) had a 1.47-fold higher risk of ≥1 oral health problem. CONCLUSION: Though the perceived oral health is relatively good, oral complications following childhood cancer treatment are prevalent in CCS. This underlines that attention to impaired oral health and awareness on this topic is mandatory and regular visits to the dentist should be a part of long-term follow-up care.
Published: 2023

17. Questionnaire- and linkage-based outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER study part 1.

Author: Teepen, J.C., Kok, J.L., Feijen, E.A.M., Loonen, J.J., Heuvel-Eibrink, M.M. van den, Pal, H.J. van der, Tissing, W.J.E., Bresters, D., Versluys, B., Grootenhuis, M.A., Louwerens, M., Neggers, S.J., Santen, H.M. van, Vries, Andrica de, Janssens, G.O., Hartogh, J.G. den, Leeuwen, F.E. van, Hollema, N., Streefkerk, N., Kilsdonk, E., Heiden-van der Loo, M., Dulmen-den Broeder, E. van, Ronckers, C.M., Kremer, L.C.M., Teepen, J.C., Kok, J.L., Feijen, E.A.M., Loonen, J.J., Heuvel-Eibrink, M.M. van den, Pal, H.J. van der, Tissing, W.J.E., Bresters, D., Versluys, B., Grootenhuis, M.A., Louwerens, M., Neggers, S.J., Santen, H.M. van, Vries, Andrica de, Janssens, G.O., Hartogh, J.G. den, Leeuwen, F.E. van, Hollema, N., Streefkerk, N., Kilsdonk, E., Heiden-van der Loo, M., Dulmen-den Broeder, E. van, Ronckers, C.M., and Kremer, L.C.M.
Abstract: Item does not contain fulltext, BACKGROUND: Childhood cancer survivors are at risk for developing long-term adverse health outcomes. To identify the risk of and risk factors for specific health outcomes, well-established cohorts are needed with detailed information on childhood cancer diagnosis, treatment, and health outcomes. We describe the design, methodology, characteristics, and data availability of the Dutch Childhood Cancer Survivor Study LATER cohort (1963-2001) part 1; questionnaire and linkage studies. METHODS: The LATER cohort includes 5-year childhood cancer survivors, diagnosed in the period 1963-2001, and before the age of 18 in any of the seven former pediatric oncology centers in the Netherlands. Information on health outcomes from survivors and invited siblings of survivors was collected by questionnaires and linkages to medical registries. RESULTS: In total, 6165 survivors were included in the LATER cohort. Extensive data on diagnosis and treatment have been collected. Information on a variety of health outcomes has been ascertained by the LATER questionnaire study and linkages with several registries for subsequent tumors, health care use, and hospitalizations. CONCLUSION: Research with data of the LATER cohort will provide new insights into risks of and risk factors for long-term health outcomes. This can enhance risk stratification for childhood cancer survivors and inform surveillance guidelines and development of interventions to prevent (the impact of) long-term adverse health outcomes. The data collected will be a solid baseline foundation for future follow-up studies.
Published: 2023

18. Desire for children among male survivors of childhood cancer: A DCCSS LATER study.

Author: Claessens, J.J.M., Penson, A., Bronkhorst, E.M., Kremer, L.C.M., Dulmen-den Broeder, E. van, Heiden-van der Loo, M., Tissing, W.J.E., Pal, H.J. van der, Blijlevens, N.M.A., Heuvel-Eibrink, M.M. van den, Versluys, A.B., Bresters, D., Ronckers, C.M., Walraven, I., Beerendonk, C.C., Loonen, J.J., Claessens, J.J.M., Penson, A., Bronkhorst, E.M., Kremer, L.C.M., Dulmen-den Broeder, E. van, Heiden-van der Loo, M., Tissing, W.J.E., Pal, H.J. van der, Blijlevens, N.M.A., Heuvel-Eibrink, M.M. van den, Versluys, A.B., Bresters, D., Ronckers, C.M., Walraven, I., Beerendonk, C.C., and Loonen, J.J.
Abstract: Item does not contain fulltext, BACKGROUND: Knowledge of the desire for children among childhood cancer survivors (CCSs) is scarce. This study evaluated the desire for children in male CCSs in comparison with male siblings. METHODS: A nationwide cohort study was conducted as part of the Dutch Childhood Cancer Survivor Study LATER study: 1317 male CCSs and 407 male sibling controls completed a questionnaire addressing the desire for children. Logistic regression analyses were used to explore the independent association between survivorship status and the desire for children. Furthermore, additional analyses were performed to identify which cancer-related factors were associated with the desire for children in male CCSs. RESULTS: After adjustments for the age at assessment, the percentage of men who had a desire for children was significantly lower among CCSs compared with the siblings (74% vs. 82%; odds ratio [OR], 0.61; 95% CI, 0.46-0.82; p = .001). The association between survivorship status and the desire for children was attenuated after adjustments for marital status, level of education, and employment status (OR, 0.83; 95% CI, 0.61-1.14; p = .250). The percentage of men who had an unfulfilled desire for children remained significantly higher among CCSs compared with the siblings after adjustments for sociodemographic factors (25% vs. 7%; OR, 5.14; 95% CI, 2.48-10.64; p < .001). CONCLUSIONS: The majority of male CCSs have a desire for children. The likelihood of having to deal with an unfulfilled desire for children is 5 times higher among CCSs compared with their siblings. This insight is important for understanding the needs and experienced problems of CCSs regarding family planning and fertility issues.
Published: 2023

19. Clinical evaluation of late outcomes in Dutch childhood cancer survivors: Methodology of the DCCSS LATER 2 study.

Author: Feijen, E.A.M., Teepen, J.C., Dulmen-den Broeder, E. van, Heuvel-Eibrink, M.M. van den, Heiden-van der Loo, M., Pal, H.J. van der, Vries, A.C.M. de, Louwerens, M., Bresters, D., Versluys, B., Ridder, H. de, Veening, M., Leeuwen, F.E. van, Grootenhuis, M., Maurice-Stam, H., Santen, H.M. van, Neggers, S.J., Pluijm, S., Hartogh, J. den, Ronckers, C.M., Tissing, W.J.E., Groot-Loonen, J.J., Kremer, L.C.M., Feijen, E.A.M., Teepen, J.C., Dulmen-den Broeder, E. van, Heuvel-Eibrink, M.M. van den, Heiden-van der Loo, M., Pal, H.J. van der, Vries, A.C.M. de, Louwerens, M., Bresters, D., Versluys, B., Ridder, H. de, Veening, M., Leeuwen, F.E. van, Grootenhuis, M., Maurice-Stam, H., Santen, H.M. van, Neggers, S.J., Pluijm, S., Hartogh, J. den, Ronckers, C.M., Tissing, W.J.E., Groot-Loonen, J.J., and Kremer, L.C.M.
Abstract: Item does not contain fulltext, BACKGROUND: Childhood cancer survivors face late health problems; despite advances in research, details on risk remain unclear. We describe the methodological aspects of the Dutch Childhood Cancer Survivor Study (DCCSS) cross-sectional clinical study (LATER 2 study). PROCEDURE: From the multi-center DCCSS LATER cohort of 6165 five-year survivors diagnosed during 1963-2001, we invited 4735 eligible survivors in 2016, as well as siblings and parents of survivors. Gaps in evidence identified during development of surveillance guidelines were translated into clinical research questions for 16 outcome-specific subprojects. The regular care visit to the LATER outpatient clinic forms the backbone of outcome assessment complemented with research-defined measurements (physical examination, clinical tests, questionnaires). Furthermore, blood/saliva samples were taken for deoxyribonucleic acid (DNA) extraction. RESULTS: In total, 2519 (53.2%) survivors participated in the LATER 2 study. When comparing participants with nonparticipants, we observed that males, CNS survivors, and those treated with surgery only were less likely to participate. Of the participating survivors, 49.3% were female. Median time since childhood cancer diagnosis was 26.9 years (range 14.8-54.7 years) and median attained age was 34.4 years (range 15.4-66.6 years). CONCLUSIONS: The high-quality data generated in the LATER 2 study will provide valuable insights into risks of and risk factors for clinical and physical and psychosocial health outcomes and factors for early recognition of those health outcomes in long-term childhood cancer survivors. This will contribute to fill in important gaps in knowledge and improve the quality of life and care for childhood cancer survivors.
Published: 2023

20. Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER): a cross-sectional study.

Author: Atteveld, Jenneke van, Winter, D.T.C. de, Pluimakers, V.G., Fiocco, M., Nievelstein, R.A., Hobbelink, M.G., Kremer, L.C.M., Grootenhuis, M.A., Maurice-Stam, H., Tissing, W.J.E., Vries, A.C.M. de, Loonen, J.J., Dulmen-den Broeder, E. van, Pal, H.J. van der, Pluijm, S.M.F., Heiden-van der Loo, M., Versluijs, A.B., Louwerens, M., Bresters, D., Santen, H.M. van, Hoefer, I., Berg, S.A. van den, Hartogh, J. den, Hoeijmakers, J.H.J., Neggers, S.J., Heuvel-Eibrink, M.M. van den, Atteveld, Jenneke van, Winter, D.T.C. de, Pluimakers, V.G., Fiocco, M., Nievelstein, R.A., Hobbelink, M.G., Kremer, L.C.M., Grootenhuis, M.A., Maurice-Stam, H., Tissing, W.J.E., Vries, A.C.M. de, Loonen, J.J., Dulmen-den Broeder, E. van, Pal, H.J. van der, Pluijm, S.M.F., Heiden-van der Loo, M., Versluijs, A.B., Louwerens, M., Bresters, D., Santen, H.M. van, Hoefer, I., Berg, S.A. van den, Hartogh, J. den, Hoeijmakers, J.H.J., Neggers, S.J., and Heuvel-Eibrink, M.M. van den
Abstract: 01 april 2023, Item does not contain fulltext, BACKGROUND: Childhood cancer survivors appear to be at increased risk of frailty and sarcopenia, but evidence on the occurrence of and high-risk groups for these aging phenotypes is scarce, especially in European survivors. The aim of this cross-sectional study was to assess the prevalence of and explore risk factors for pre-frailty, frailty, and sarcopenia in a national cohort of Dutch childhood cancer survivors diagnosed between 1963 and 2001. METHODS: Eligible individuals (alive at the time of study, living in the Netherlands, age 18-45 years, and had not previously declined to participate in a late-effects study) from the Dutch Childhood Cancer Survivor Study (DCCSS-LATER) cohort were invited to take part in this cross-sectional study. We defined pre-frailty and frailty according to modified Fried criteria, and sarcopenia according to the European Working Group on Sarcopenia in Older People 2 definition. Associations between these conditions and demographic and treatment-related as well as endocrine and lifestyle-related factors were estimated with two separate multivariable logistic regression models in survivors with any frailty measurement or complete sarcopenia measurements. FINDINGS: 3996 adult survivors of the DCCSS-LATER cohort were invited to participate in this cross-sectional study. 1993 non-participants were excluded due to lack of response or a decline to participate and 2003 (50·1%) childhood cancer survivors aged 18-45 years were included. 1114 (55·6%) participants had complete frailty measurements and 1472 (73·5%) participants had complete sarcopenia measurements. Mean age at participation was 33·1 years (SD 7·2). 1037 (51·8%) participants were male, 966 (48·2%) were female, and none were transgender. In survivors with complete frailty measurements or complete sarcopenia measurements, the percentage of pre-frailty was 20·3% (95% CI 18·0-22·7), frailty was 7·4% (6·0-9·0), and sarcopenia was 4·4% (3·5-5·6). In the models for pre-frailty, underweigh
Published: 2023

21. Extensive Cardiac Function Analyses Using Contemporary Echocardiography in Childhood Cancer Survivors: A DCCSS LATER Study.

Author: Merkx, R., Leerink, J.M., Feijen, E.Lieke A.M., Baat, E.C. de, Bellersen, L., Bresters, D., Dalen, E.C. van, Dulmen-den Broeder, E. van, Heiden-van der Loo, M. van der, Heuvel-Eibrink, M.M. van den, Kok, J.L., Louwerens, M., Maas, A.H.E.M., Neggers, S.J., Ronckers, C.M., Teepen, J.C., Teske, A.J., Tissing, W.J.E., Vries, A.C.M. de, Weijers, G., Korte, C.L. de, Loonen, J.J., Mavinkurve-Groothuis, A.M.C., Pal, H.J.H. van der, Kremer, L.C.M., Kok, W.E., Kapusta, L., Merkx, R., Leerink, J.M., Feijen, E.Lieke A.M., Baat, E.C. de, Bellersen, L., Bresters, D., Dalen, E.C. van, Dulmen-den Broeder, E. van, Heiden-van der Loo, M. van der, Heuvel-Eibrink, M.M. van den, Kok, J.L., Louwerens, M., Maas, A.H.E.M., Neggers, S.J., Ronckers, C.M., Teepen, J.C., Teske, A.J., Tissing, W.J.E., Vries, A.C.M. de, Weijers, G., Korte, C.L. de, Loonen, J.J., Mavinkurve-Groothuis, A.M.C., Pal, H.J.H. van der, Kremer, L.C.M., Kok, W.E., and Kapusta, L.
Abstract: 01 augustus 2023, Contains fulltext : 295910.pdf (Publisher’s version ) (Open Access), BACKGROUND: Childhood cancer survivors (CCS) are at risk for cardiotoxicity. OBJECTIVES: We sought to assess how cardiac dysfunction measurements in CCS overlap and are differentially influenced by risk factors. METHODS: This cross-sectional Dutch Childhood Cancer Survivor Study evaluated echocardiograms of 1,397 ≥5-year CCS and 277 siblings. Of CCS, n = 1,254 received cardiotoxic (anthracyclines/mitoxantrone/radiotherapy involving the heart region [RT(heart)]) and n = 143 received potentially cardiotoxic (cyclophosphamide, ifosfamide, or vincristine) therapy. We assessed demographic, treatment-related, and traditional cardiovascular risk factors for cardiac dysfunction using multivariable logistic regression. RESULTS: CCS were a median of 26.7 years after diagnosis; 49% were women. Abnormal left ventricular ejection fraction (LVEF) (defined as <52% in men, <54% in women) occurred most commonly in CCS treated with anthracyclines and RT(heart) combined (38%). Age/sex-specific abnormal global longitudinal strain (GLS) occurred most commonly in CCS treated with RT(heart), either with (41%) or without (38%) anthracyclines. Of CCS with normal LVEF, 20.2% showed abnormal GLS. Diastolic dysfunction grade ≥II was rare. Abnormal LVEF was mainly associated with female sex, anthracycline dose, and only in women, RT(heart) dose. Abnormal GLS was associated with female sex, RT(heart) dose, diastolic blood pressure, and only in women, anthracycline dose. Cyclophosphamide, ifosfamide, and vincristine were not associated with LVEF or GLS. Compared with siblings, CCS showed higher risk of abnormal LVEF (OR: 2.9; 95% CI: 1.4-6.6) and GLS (OR: 2.1; 95% CI: 1.2-3.7), independent of (potentially) cardiotoxic treatment-related and cardiovascular risk factors. CONCLUSIONS: Abnormal LVEF and GLS constitute complementary measures of systolic dysfunction among long-term CCS. Their diagnostic value may differ according to cardiotoxic exposures. Also, CCS have residual, unexplained risk of car
Published: 2023

22. Psychosexual development, sexual functioning and sexual satisfaction in long-term childhood cancer survivors: DCCSS-LATER 2 sexuality substudy.

Author: Priboi, C., Gorp, M. van, Maurice-Stam, H., Michel, G., Kremer, L.C.M., Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Ronckers, C.M., Bresters, D., Louwerens, M., Neggers, S.J.C.C.M., Heiden-van der Loo, M. van der, Dulmen-den Broeder, E. van, Grootenhuis, M., Priboi, C., Gorp, M. van, Maurice-Stam, H., Michel, G., Kremer, L.C.M., Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Ronckers, C.M., Bresters, D., Louwerens, M., Neggers, S.J.C.C.M., Heiden-van der Loo, M. van der, Dulmen-den Broeder, E. van, and Grootenhuis, M.
Abstract: 01 augustus 2023, Contains fulltext : 295951.pdf (Publisher’s version ) (Open Access), OBJECTIVES: Childhood cancer may negatively impact childhood cancer survivors' (CCS) sexuality. However, this is an understudied research area. We aimed to describe the psychosexual development, sexual functioning and sexual satisfaction of CCS, and identify determinants for these outcomes. Secondarily, we compared the outcomes of a subsample of emerging adult CCS to the Dutch general population. METHODS: From the Dutch Childhood Cancer Survivor Study LATER cohort (diagnosed 1963-2001), 1912 CCS (18-71 years, 50.8% male) completed questions on sexuality, psychosocial development, body perception, mental and physical health. Multivariable linear regressions were used to identify determinants. Sexuality of CCS age 18-24 (N = 243) was compared to same-aged references using binomial tests and t-tests. RESULTS: One third of all CCS reported hindered sexuality due to childhood cancer, with insecure body the most often reported reason (44.8%). Older age at study, lower education, surviving central nervous system cancer, poorer mental health and negative body perception were identified as determinants for later sexual debut, worse sexual functioning and/or sexual satisfaction. CCS age 18-24 showed significantly less experience with kissing (p = 0.014), petting under clothes (p = 0.002), oral (p = 0.016) and anal sex (p = 0.032) when compared to references. No significant differences with references were found for sexual functioning and sexual satisfaction, neither among female CCS nor male CCS age 18-24. CONCLUSIONS: Emerging adult CCS reported less experience with psychosexual development, but similar sexual functioning and sexual satisfaction compared to references. We identified determinants for sexuality, which could be integrated in clinical interventions for CCS at risk for reduced sexuality.
Published: 2023

23. Psychosocial outcomes in long-term Dutch adult survivors of childhood cancer: The DCCSS-LATER 2 psycho-oncology study.

Author: Maas, A, Maurice-Stam, H., Kremer, L.C.M., Aa-van Delden, A. van der, Dulmen-den Broeder, E. van, Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Ronckers, C., Neggers, S., Bresters, D., Louwerens, M., Heiden-van der Loo, M. van der, Gorp, M. van, Grootenhuis, M., Maas, A, Maurice-Stam, H., Kremer, L.C.M., Aa-van Delden, A. van der, Dulmen-den Broeder, E. van, Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Ronckers, C., Neggers, S., Bresters, D., Louwerens, M., Heiden-van der Loo, M. van der, Gorp, M. van, and Grootenhuis, M.
Abstract: Contains fulltext : 295976.pdf (Publisher’s version ) (Open Access), BACKGROUND: This study compares a comprehensive range of psychosocial outcomes of adult childhood cancer survivors (CCS) to general population-based references and identifies sociodemographic and medical risk factors. METHODS: CCS from the Dutch Childhood Cancer Survivor Study (DCCSS)-LATER cohort (diagnosed 1963-2001) part 2 (attained age ≥18 years, diagnosed <18 years, ≥5 years since diagnosis) completed the Rosenberg Self-Esteem Scale, Hospital Anxiety and Depression Scale, Distress Thermometer, Self-Rating Scale for Post-Traumatic Stress Disorder, and the Short Form-36 (Health Related Quality of Life). CCS' scores were compared with references using analysis of variances and logistic regression analysis, controlling for age and sex (p < .05). Risk factors for worse psychosocial outcomes were assessed with regression analyses (p < .05). RESULTS: CCS, N = 1797, mean age 35.4 years, 49.0% female, all ≥15 years since diagnosis, participated. Three percent reported posttraumatic stress disorder because of childhood cancer and 36.6% experienced clinical distress. CCS did not differ from references on self-esteem and anxiety but were less depressed (d = -.25), and scored poorer on all health-related quality of life scales, except for bodily pain (.01 ≤ d ≥ -.36). Female sex, lower educational attainment, not being in a relationship, and being unemployed were negatively associated with almost all psychosocial outcomes. Except for a central nervous system tumor diagnosis, few medical characteristics were associated with psychosocial outcomes. CONCLUSION: CCS appear resilient regarding mental health but have slightly poorer health-related quality of life than references. Sociodemographic characteristics and central nervous system tumors were related to most psychosocial outcomes, but no clear pattern was observed for other medical factors. Future studies should address additional factors in explaining CCS' psychosocial functioning, such as coping, social support, and ph
Published: 2023

24. Stik! Onschadelijk maken van Japanse duizendknoop

Author: Loop, J.M.M. van der, Veenhuisen, L.S. van, Kleef, H.H. van, Sluiter, A., Loo, M. te, Reinders, J., Loop, J.M.M. van der, Veenhuisen, L.S. van, Kleef, H.H. van, Sluiter, A., Loo, M. te, and Reinders, J.
Abstract: Item does not contain fulltext
Published: 2023

25. Prevalence, risk factors, and optimal way to determine overweight, obesity, and morbid obesity in the first Dutch cohort of 2338 long-term survivors of childhood cancer:a DCCSS-LATER study

Author: Pluimakers, VG, van Atteveld, JE, de Winter, DTC, Bolier, M, Fiocco, M, Nievelstein, RJAJ, Janssens, GOR, Bresters, D, van der Heiden-van der Loo, M, de Vries, ACH, Louwerens, M, van der Pal, HJ, Pluijm, SMF, Ronckers, CM, Versluijs, AB, Kremer, LCM, Loonen, JJ, van Dulmen-den Broeder, E, Tissing, WJE, van Santen, HM, van den Heuvel-Eibrink, MM, Neggers, SJCMM, Pluimakers, VG, van Atteveld, JE, de Winter, DTC, Bolier, M, Fiocco, M, Nievelstein, RJAJ, Janssens, GOR, Bresters, D, van der Heiden-van der Loo, M, de Vries, ACH, Louwerens, M, van der Pal, HJ, Pluijm, SMF, Ronckers, CM, Versluijs, AB, Kremer, LCM, Loonen, JJ, van Dulmen-den Broeder, E, Tissing, WJE, van Santen, HM, van den Heuvel-Eibrink, MM, and Neggers, SJCMM
Abstract: Background Overweight and obesity are common challenges among childhood cancer survivors. Overweight may be disguised, as survivors can have normal weight but high fat percentage (fat%) on dual-energy X-ray absorptiometry (DXA). We aimed to assess prevalence, identify determinants and biomarkers, and assess which method captures overweight best, in a nationwide cohort. Methods The prevalence of overweight and obesity, primarily defined by body mass index (BMI), was assessed in the DCCSS-LATER cohort of adult survivors treated from 1963-2002, with the LifeLines cohort as reference. The associations between risk factors and overweight metrics were investigated using logistic regression. Additional overweight metrics included DXA fat%, waist circumference (WC), waist/hip ratio (WHR), waist/height ratio (WHtR), and high-molecular-weight (HMW) adiponectin. Results A total of 2338 (mean age 35.5 years, follow-up 28.3 years) survivors participated. The overweight prevalence was 46.3% in men and 44.3% in women (obesity 11.2% and 15.9%, morbid obesity 2.4% and 5.4%), with highest rates among brain tumor survivors. Compared to controls, there was no overall increased overweight rate, but this was higher in women > 50 years, morbid obesity in men > 50 years. Overweight at cancer diagnosis (adjusted odds ratio [aOR] = 3.83, 95% CI 2.19-6.69), cranial radiotherapy (aOR = 3.21, 95% CI 1.99-5.18), and growth hormone deficiency (separate model, aOR = 1.61, 95% CI 1.00-2.59) were associated with overweight. Using BMI, WC, WHR, and WHtR, overweight prevalence was similar. Low HMW adiponectin, present in only 4.5% of survivors, was an insensitive overweight marker. Dual-energy X-ray absorptiometry–based classification identified overweight in an additional 30%, particularly after abdominal radiotherapy, total body irradiation, anthracyclines, and platinum. Conclusions Overweight occurs in almost half of long-term survivors. There was no
Published: 2023

26. Hygiënisch werken met invasieve exoten in de provincie Friesland

Author: Loop, J.M.M. van der, Veenhuisen, L.S. van, Loo, M. van de, Loop, J.M.M. van der, Veenhuisen, L.S. van, and Loo, M. van de
Abstract: Voor het veilig werken met invasieve exoten om schade aan natuur, volksgezondheid en economie te voorkomen zijn voor de provincie Friesland een uitgebreide beschrijving en adviezen voor het treffen van de hygiënemaatregelen opgenomen. Deze adviezen zijn samengevat in twee praktische werkprotocollen; een voor aquatische (watergebonden) invasieve exoten en een voor terrestrische (grondgebonden) invasieve exoten. In deze rapportage worden de volgende vier deelopdrachten uitgewerkt: 1. Inventarisatie toepassing huidige hygiënemaatregelen 2. Weergave juiste manier van hygiënisch werken 3. Knelpunten en verbeteringen aangeven 4. Uitkomsten voorgaande weergeven in werkbare protocollen
Published: 2023

27. Prevalence, risk factors and optimal way to determine overweight, obesity and morbid obesity, in the first Dutch cohort of 2,338 long-term survivors of childhood cancer: a DCCSS-LATER study

Author: Unit Opleiding Aios, Orthopaedie Onderzoek, MS Radiologie, Child Health, MS Radiotherapie, Cancer, SCT patientenzorg, PMC Medisch specialisten, PMC Research, Klinische Fysica RT, Haematologie patientenzorg, Zorg en O&O, Endocrinologie patientenzorg, Brain, Speerpunt, In Vivo NMR ISI, Pluimakers, V G, van Atteveld, J E, de Winter, D T C, Bolier, M, Fiocco, M, Nievelstein, R A J, Janssens, G O R, Bresters, D, van der Heiden-van der Loo, M, de Vries, A C H, Louwerens, M, van der Pal, H J, Pluijm, S M F, Ronckers, C M, Versluijs, A B, Kremer, L C M, Loonen, J J, van Dulmen-den Broeder, E, Tissing, W J E, van Santen, H M, van den Heuvel-Eibrink, M M, Neggers, S J C M M, Unit Opleiding Aios, Orthopaedie Onderzoek, MS Radiologie, Child Health, MS Radiotherapie, Cancer, SCT patientenzorg, PMC Medisch specialisten, PMC Research, Klinische Fysica RT, Haematologie patientenzorg, Zorg en O&O, Endocrinologie patientenzorg, Brain, Speerpunt, In Vivo NMR ISI, Pluimakers, V G, van Atteveld, J E, de Winter, D T C, Bolier, M, Fiocco, M, Nievelstein, R A J, Janssens, G O R, Bresters, D, van der Heiden-van der Loo, M, de Vries, A C H, Louwerens, M, van der Pal, H J, Pluijm, S M F, Ronckers, C M, Versluijs, A B, Kremer, L C M, Loonen, J J, van Dulmen-den Broeder, E, Tissing, W J E, van Santen, H M, van den Heuvel-Eibrink, M M, and Neggers, S J C M M
Published: 2023

28. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer

Author: Aalders, K.C., van Bommel, A.C.M., van Dalen, T., Sonke, G.S., van Diest, P.J., Boersma, L.J., and van der Heiden- van der Loo, M.
Published: 2016
Full Text: View/download PDF

29. Positive and negative survivor-specific psychosocial consequences of childhood cancer: the DCCSS-LATER 2 psycho-oncology study

Author: Maas, A., Maurice-Stam, H., Aa-van Delden, A.M. van der, Dalen, E.C. van, Dulmen-den Broeder, E. van, Tissing, W.J.E., Loonen, J.J., Pal, H.J.H. van der, Vries, A.C.H. de, Heuvel-Eibrink, M.M. van den, Janssens, G.O., Ronckers, C., Neggers, S., Bresters, D., Louwerens, M., Versluys, B.A.B., Heiden-van der Loo, M. van der, Kremer, L.C.M., Gorp, M. van, Grootenhuis, M.A., and Dutch LATER Study Group
Subjects: Quality of life, Impact of cancer, Long-term survivorship, Childhood cancer survivors, Psychosocial
Abstract: Purpose: Numerous studies investigated generic psychosocial outcomes in survivors of childhood cancer (CCS). The present study aimed to describe survivor-specific psychosocial consequences in CCS, and to identify socio-demographic and medical associated factors. Methods: CCS from the Dutch Childhood Cancer Survivor Study (DCCSS)-LATER cohort (diagnosed 1963-2001) part 2 (age >= 18 years, diagnosed < 18 years, >= 5 years since diagnosis) completed the Benefit & Burden Scale (BBSC) and the Impact of Cancer-Childhood Cancer (IOC-CS). Items were scored on a 5-point Likert scale (range 1-5). We examined outcomes with descriptive statistics, and socio-demographic and medical associated factors with regression analyses, corrected for multiple testing (p < 0.004). Results: CCS, N = 1713, age mean (M) 36 years, 49% female, >= 15 years since diagnosis, participated. On average, CCS reported 'somewhat' Benefit (M = 2.9), and 'not at all' to 'a little' Burden (M = 1.5) of childhood cancer. Average scores on IOC-CS' positive impact scales ranged from 2.5 (Personal Growth) to 4.1 (Socializing), and on the negative impact scales from 1.4 (Financial Problems) to 2.4 (Thinking/Memory). Apart from cognitive problems, CCS reported challenges as worries about relationship status, fertility, and how cancer had affected siblings. Female sex was associated with more Personal Growth, and more negative impact. CCS more highly educated, partnered, and employed had higher positive and lower negative impact. CCS older at diagnosis reported more positive impact. CNS tumor survivors and those who had head/cranium radiotherapy had higher negative impact. CNS tumor survivors reported less positive impact. Conclusion and implications: The majority of CCS reported positive impact of cancer while most CCS reported little negative impact. While this may indicate resiliency in most CCS, health care providers should be aware that they can also experience survivor-specific challenges that warrant monitoring/screening, information provision and psychosocial support.
Published: 2023

30. Psychosocial developmental milestones of young adult survivors of childhood cancer

Author: Maurice-Stam, H., Erp, L.M.E. van, Maas, A, Oers, H.A. van, Kremer, L.C., Dulmen-den Broeder, E. van, Tissing, W.J.E., Loonen, J.J., Pal, H.J. van der, Beek, L.R., Vries, A.C.M. de, Heuvel-Eibrink, M.M. van den, Ronckers, C.M., Bresters, D., Louwerens, M., Heiden-van der Loo, M., Huizinga, G.A., and Grootenhuis, M.A.
Subjects: Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract: Contains fulltext : 251635.pdf (Publisher’s version ) (Open Access) PURPOSE: The study aimed to compare the psychosocial development of young adult survivors of childhood cancer (YACCS) with a norm group of young adults from the general population. METHODS: From 2017 to 2020, 558 YACCS (18-30 years, 51% female, 10.9% CNS cancer) who participated in the Dutch Childhood Cancer Survivor Study (DCCSS) LATER cohort (diagnosed 1963-2001) part 2 completed the Course of Life Questionnaire (CoLQ), assessing the achievement of milestones. Items were grouped into the scales autonomy, psychosexual, and social development. Differences between YACCS and norm group were examined with ANOVA and Cohen's d (CoLQ scales) and with logistic regression analysis and odds ratio (OR) (CoLQ items), for the total group and YACCS of CNS cancer. RESULTS: The total group of YACCS did not report a less favorable psychosocial development than the norm group. YACCS of CNS cancer scored lower than the norm group (p < 0.001) on the scales autonomy (d = - 0.36) and psychosexual (d = - 0.46). Additionally, on half of the items of autonomy (0.25 ≤ OR ≤ 0.34), psychosexual (0.30 ≤ OR ≤ 0.48), and social (0.23 ≤ OR ≤ 0.47) development, YACCS of CNS cancer were less likely (p < 0.01) than the norm group to have achieved the milestones. CONCLUSION: Overall, psychosocial development of YACCS was as favorable as the norm, but YACCS of CNS cancer were at risk of an unfavorable psychosocial development in all domains. Monitoring psychosocial development should be included in the standards of psychosocial care, especially for CNS cancer patients and survivors, to be able to trace delay. Personalized interventions should be offered to improve the psychosocial development in an early stage.
Published: 2022

31. In 3 stappen naar een succesvolle CRM-strategie

Author: de Rooij, Pieter, de Jong, M, Van der Loo, M., Haaster, J., and Academy for Leisure & Events
Published: 2023

32. Een goede CRM strategie zorgt voor meer verbinding met jouw bezoekers

Author: de Rooij, Pieter, De Jong, M., Van der Loo, M., Haaster, J., and Academy for Leisure & Events
Published: 2023

33. Oncological Safety and Potential Cost Savings of Routine vs Selective Histopathological Examination After Appendectomy Results of the Multicenter, Prospective, Cross-Sectional FANCY Study

Author: Bastiaenen, Vivian P., de Jonge, Joske, Corten, Bartholomeus J. G. A., de Savornin Lohman, Elise A. J., Kraima, Anne C., Swank, Hilko A., van Vliet, Jaap L. P., van Acker, Gijs J. D., van Geloven, Anna A. W., in'tHof, Klaas H., Koens, Lianne, de Reuver, Philip R., van Rossem, Charles C., Slooter, Gerrit D., Tanis, Pieter J., Terpstra, Valeska, Dijkgraaf, Marcel G. W., Bemelman, Willem A., Amelung, F. J., Atema, J. J., Bessems, S., Beunders, A. A. M., Bodewes, T. C. F., den Boer, F. C., Boerma, D., Boerma, E. G., van den Boezem, P., Bökkerink, W. J. V., van den Boogaart, D., Boogerd, L. S. F., Bouwman, H., Broos, A., Brueren, L. O., Bruinsma, W. E., Bruns, E. R. C., Castelijns, P. S. S., de Castro, S. M. M., Consten, E. C. J., Crolla, R. M. P. H., Dam, M. J., Dang, Q., Dekker, J. W. T., Deroose, J. P., Devriendt, S., Dijkema, E. J., Dijkstra, N., Driessen, M. L. S., van Duijvendijk, P., Duinhouwer, L. E., van Duyn, E. B., el-Massoudi, Y., Elfrink, A. K. E., Elschot, J. H., van Essen, J. A., Ferenschild, F. T. J., Gans, S. L., Gaznay, C., Geraedts, A. C. M., van Gessel, B. S. H., Giesen, L. J. X., van Gils, N., Gorgec, B., Gorter, R. R., Govaert, K. M., Greuter, G. N., van Grevenstein, W. M. U., Groot, L., Hardy, J. C. A., Heemskerk, J., Heeren, J. F., Heidotting, J., Heikens, J. T., Hosseinzoi, E., van Iersel, J. J., Inberg, B., Jansen, L. J., Jens, A. J. T., Jilesen, A. P. J., Joosten, M., de Jong, L., Keijzers, M., Klicks, R. J., Kloppenberg, F. W. H., Koedam, T. W. A., Koëter, T., Konsten, J. L. M., Koolen, L. J. E. R., Kruyt, Ph. M., Lange, J. F. M., Lavrijssen, B. D. A., de Leede, E. M., Leliefeld, P. H. C., Linnemann, R. J. A., Lo, G. C., van de Loo, M., Lubbert, P. H. W., Holzik, M. F. Lutke, Manusama, E., Masselink, I., Matthée, E. P. C., Matthijsen, R. A., Mearadji, A., Melenhorst, J., Merkus, J. W. S., Michiels, T. D., Moes, D. E., Moossdorff, M., Mulder, E., Nallayici, E. G., Neijenhuis, P. A., Nielsen, K., Nieuwenhuijzen, G. A. P., Nijhuis, J., Okkema, S., Olthof, P. B., van Onkelen, R. S., van Oostendorp, S. E., Plaisier, P. W., Polle, S. W., Reiber, B. M. M., Reichert, F. C. M., van Rest, K. L. C., van Rijn, R., Roozendaal, N. C., de Ruijter, W. M. J., Schat, E., Scheerhoorn, J., Scheijmans, J. C. G., Schimmer, J., Schipper, R. J., Schouten, R., Schreurs, W. H., Schrijver, W. A. M. E., Shapiro, J., Siemons, A., Silvis, R., Simkens, G. A., Smakman, N., Smeets, B. J. J., Sonneveld, D. J. A., van Suijlichem, M., Talsma, A. K., Thoolen, J. M. M., van Tol, R. R., Tournoij, E., Tseng, L. N. L., Tuynman, J. B., van der Velde, K., Veltkamp, S. C., Verbeek, F. P. R., Verdaasdonk, E., Verhaak, T., Verheuvel, N. C., Vermaas, M., Verseveld, M., Vlek, S., Vogels, S., van de Voort, E. M. F., van Vugt, S. T., Wegdam, J. A., Wennekers, M. M., Wiering, B., de Wijkerslooth, E. M. L., Wijkmans, A. A., Wijnhoven, B. P. L., Witjes, C. D. M., Wolfhagen, N., de Zeeuw, S., van Zoonen, G., Surgery, Erasmus MC other, Obstetrics & Gynecology, Department of Strategic Management and Entrepreneurship, Neurology, Rotterdam School of Management, Cardiology, Gastroenterology & Hepatology, Radiology & Nuclear Medicine, Otorhinolaryngology and Head and Neck Surgery, Emergency Medicine, Public Health, Plastic and Reconstructive Surgery and Hand Surgery, Dermatology, Clinical Chemistry, Internal Medicine, Erasmus School of Social and Behavioural Sciences, General Practice, Radiotherapy, Research & Education, Rehabilitation Medicine, Urology, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, Cancer Center Amsterdam, Hematology laboratory, VU University medical center, CCA - Cancer Treatment and quality of life, and CCA - Imaging and biomarkers
Subjects: medicine.medical_specialty, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, business.industry, General surgery, Medicine, Surgery, Histopathological examination, business, Cost savings
Abstract: Objective: To investigate the oncological safety and potential cost savings of selective histopathological examination after appendectomy. Background: The necessity of routine histopathological examination after appendectomy has been questioned, but prospective studies investigating the safety of a selective policy are lacking. Methods: In this multicenter, prospective, cross-sectional study, inspection and palpation of the (meso)appendix was performed by the surgeon in patients with suspected appendicitis. The surgeon's opinion on additional value of histopathological examination was reported before sending all specimens to the pathologist. Main outcomes were the number of hypothetically missed appendiceal neoplasms with clinical consequences benefiting the patient (upper limit two-sided 95% confidence interval below 3:1000 considered oncologically safe) and potential cost savings after selective histopathological examination. Results: Seven thousand three hundred thirty-nine patients were included. After a selective policy, 4966/7339 (67.7%) specimens would have been refrained from histopathological examination. Appendiceal neoplasms with clinical consequences would have been missed in 22/4966 patients. In 5/22, residual disease was completely resected during additional surgery. Hence, an appendiceal neoplasm with clinical consequences benefiting the patient would have been missed in 1.01:1000 patients (upper limit 95% confidence interval 1.61:1000). In contrast, twice as many patients (10/22) would not have been exposed to potential harm due to re-resections without clear benefit, whereas consequences were neither beneficial nor harmful in the remaining seven. Estimated cost savings established by replacing routine for selective histopathological examination were 725,400 per 10,000 patients. Conclusions: Selective histopathological examination after appendectomy for suspected appendicitis is oncologically safe and will likely result in a reduction of pathologists' workload, less costs, and fewer re-resections without clear benefit.
Published: 2023

34. Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients

Author: Fernández, D.I., Diender, M.G., Hermida-Nogueira, L., Huang, Jingnan, Veiras, S., Henskens, Y.M.C., Loo, M. te, Heemskerk, J.W.M., Kuijpers, M.J.E., and García, Á.
Subjects: Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract: Contains fulltext : 294565.pdf (Publisher’s version ) (Open Access) INTRODUCTION: The protein tyrosine phosphatase SHP2 (PTPN11) is a negative regulator of glycoprotein VI (GPVI)-induced platelet signal under certain conditions. Clinical trials with derivatives of the allosteric drug SHP099, inhibiting SHP2, are ongoing as potential therapy for solid cancers. Gain-of-function mutations of the PTPN11 gene are observed in part of the patients with the Noonan syndrome, associated with a mild bleeding disorder. Assessment of the effects of SHP2 inhibition in platelets from controls and Noonan syndrome patients. MATERIALS AND METHODS: Washed human platelets were incubated with SHP099 and stimulated with collagen-related peptide (CRP) for stirred aggregation and flow cytometric measurements. Whole-blood microfluidics assays using a dosed collagen and tissue factor coating were performed to assess shear-dependent thrombus and fibrin formation. Effects on clot formation were evaluated by thromboelastometry. RESULTS: Pharmacological inhibition of SHP2 did not alter GPVI-dependent platelet aggregation under stirring, but it enhanced integrin αIIbβ3 activation in response to CRP. Using whole-blood microfluidics, SHP099 increased the thrombus buildup on collagen surfaces. In the presence of tissue factor and coagulation, SHP099 increased thrombus size and reduced time to fibrin formation. Blood from PTPN11-mutated Noonan syndrome patients, with low platelet responsiveness, after ex vivo treatment with SHP099 showed a normalized platelet function. In thromboelastometry, SHP2 inhibition tended to increase tissue factor-induced blood clotting profiles with tranexamic acid, preventing fibrinolysis. CONCLUSION: Pharmacological inhibition of SHP2 by the allosteric drug SHP099 enhances GPVI-induced platelet activation under shear conditions with a potential to improve platelet functions of Noonan syndrome patients.
Published: 2023

35. Risk and determinants of low and very low bone mineral density and fractures in a national cohort of Dutch adult childhood cancer survivors (DCCSS-LATER): a cross-sectional study

Author: Atteveld, J.E. van, Winter, D.T.C. de, Pluimakers, V.G., Fiocco, M., Nievelstein, R.A.J., Hobbelink, M.G.G., Vries, A.C.H. de, Loonen, J.J., Dulmen-den Broeder, E. van, Pal, H.J. van der, Pluijm, S.M.F., Kremer, L.C.M., Ronckers, C.M., Heiden-van der Loo, M. van der, Versluijs, A.B., Louwerens, M., Bresters, D., Santen, H.M. van, Olsson, D.S., Hoefer, I., Berg, S.A.A. van den, Hartogh, J. den, Tissing, W.J.E., Neggers, S.J.C.M.M., Heuvel-Eibrink, M.M. van den, Dutch LATER Study Grp, Pediatrics, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), Clinical Chemistry, and Internal Medicine
Subjects: Endocrinology, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Endocrinology, Diabetes and Metabolism, Internal Medicine, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract: Background: Childhood cancer survivors are at risk of developing skeletal comorbidities later in life. We aimed to assess risk factors for low and very low bone mineral density (BMD), and the risk of and risk factors for any fractures and vertebral fractures in a national cohort of Dutch adult childhood cancer survivors.Methods: In this cross-sectional study, we used data from the DCCSS LATER cohort, which comprised individuals who were alive for at least 5 years after diagnosis of childhood cancer (ie, histologically confirmed malignancies or Langerhans cell histiocytosis), were diagnosed before the age of 19 years, and who had been treated at one of seven Dutch paediatric oncology centres between 1963 and 2002 (hereafter referred to as survivors). For this study, we invited survivors aged 18-45 years, who were alive as of Oct 10, 2016, living in the Netherlands, and who were deemed eligible by their treating physician to participate. We assessed BMD using dual-energy x-ray absorptiometry (DXA). Self-reported fractures that occurred at least 5 years after cancer diagnosis were assessed using available medical history and compared with population-level data from the Swedish national registry. We assessed vertebral fractures in a subset of participants using a vertebral fracture assessment. We assessed associations between the occurrence of low (Z-score of
Published: 2023

36. MWR: Microwave Radiometer for the Juno Mission to Jupiter

Author: Janssen, M. A., Oswald, J. E., Brown, S. T., Gulkis, S., Levin, S. M., Bolton, S. J., Allison, M. D., Atreya, S. K., Gautier, D., Ingersoll, A. P., Lunine, J. I., Orton, G. S., Owen, T. C., Steffes, P. G., Adumitroaie, V., Bellotti, A., Jewell, L. A., Li, C., Li, L., Misra, S., Oyafuso, F. A., Santos-Costa, D., Sarkissian, E., Williamson, R., Arballo, J. K., Kitiyakara, A., Ulloa-Severino, A., Chen, J. C., Maiwald, F. W., Sahakian, A. S., Pingree, P. J., Lee, K. A., Mazer, A. S., Redick, R., Hodges, R. E., Hughes, R. C., Bedrosian, G., Dawson, D. E., Hatch, W. A., Russell, D. S., Chamberlain, N. F., Zawadski, M. S., Khayatian, B., Franklin, B. R., Conley, H. A., Kempenaar, J. G., Loo, M. S., Sunada, E. T., Vorperion, V., and Wang, C. C.
Published: 2017
Full Text: View/download PDF

37. Frailty and sarcopenia within the earliest Dutch childhood cancer survivor cohort (n=2,003)

Author: Atteveld, J.E. van, Winter, D.T.C. de, Pluimakers, V.G., Fiocco, M., Nievelstein, R.A.J., Hobbelink, M.G.G., Kremer, L.C.M., Ronckers, C.M., Grootenhuis, M.A., Maurice-Stam, H., Tissing, W.J.E., Vries Andrica, C.H. de, Loonen, J.J., Dulmen-den Broeder, E. van, Pal, H.J. van der, Pluijm, S., Heiden-van der Loo, M. van der, Versluys, B., Louwerens, M., Bresters, D., Santen, H.M. van, Hoefer, I., Berg, S.A.A., van den, Hoeijmakers, J.H.J., Neggers, S.J.C.M.M., and Heuvel-Eibrink, M.M. van den
Subjects: Immunology, Cell Biology, Hematology, Biochemistry
Published: 2022

38. Prognostic Factors in Radionecrosis Following Post-Operative Stereotactic Brain Radiation Therapy from a Multicentric Retrospective Analysis

Author: Roquet, N., Beddok, A., Loo, M., Calais, G., Crehange, G., Chapet, S., and Frédéric-Moreau, T.
Published: 2024
Full Text: View/download PDF

39. MWR: Microwave Radiometer for the Juno Mission to Jupiter

Author: Janssen, M. A., primary, Oswald, J. E., additional, Brown, S. T., additional, Gulkis, S., additional, Levin, S. M., additional, Bolton, S. J., additional, Allison, M. D., additional, Atreya, S. K., additional, Gautier, D., additional, Ingersoll, A. P., additional, Lunine, J. I., additional, Orton, G. S., additional, Owen, T. C., additional, Steffes, P. G., additional, Adumitroaie, V., additional, Bellotti, A., additional, Jewell, L. A., additional, Li, C., additional, Li, L., additional, Misra, S., additional, Oyafuso, F. A., additional, Santos-Costa, D., additional, Sarkissian, E., additional, Williamson, R., additional, Arballo, J. K., additional, Kitiyakara, A., additional, Ulloa-Severino, A., additional, Chen, J. C., additional, Maiwald, F. W., additional, Sahakian, A. S., additional, Pingree, P. J., additional, Lee, K. A., additional, Mazer, A. S., additional, Redick, R., additional, Hodges, R. E., additional, Hughes, R. C., additional, Bedrosian, G., additional, Dawson, D. E., additional, Hatch, W. A., additional, Russell, D. S., additional, Chamberlain, N. F., additional, Zawadski, M. S., additional, Khayatian, B., additional, Franklin, B. R., additional, Conley, H. A., additional, Kempenaar, J. G., additional, Loo, M. S., additional, Sunada, E. T., additional, Vorperion, V., additional, and Wang, C. C., additional
Published: 2017
Full Text: View/download PDF

40. Nitrogen acquisition and resource allocation strategies in temperate seagrass Zostera nigricaulis: Uptake, assimilation and translocation processes

Author: Nayar, S., Loo, M. G. K., Tanner, J. E., Longmore, A. R., and Jenkins, G. P.
Published: 2018
Full Text: View/download PDF

41. The validation study on a three-dimensional burn estimation smart-phone application: accurate, free and fast?

Author: Cheah, A. K. W., Kangkorn, T., Tan, E. H., Loo, M. L., and Chong, S. J.
Published: 2018
Full Text: View/download PDF

42. Original Research Hypertension in long-term childhood cancer survivors after treatment with potentially nephrotoxic therapy; DCCSS-LATER 2: Renal study

Author: Kooijmans, E.C.M., Pal, H.J.H. van der, Pluijm, S.M.F., Bresters, D., Dulmen-den Broeder, E. van, Heiden-van der Loo, M. van der, Heuvel-Eibrink, M.M. van den, Kremer, L.C.M., Loonen, J.J., Louwerens, M., Neggers, S.J.C., Pilon, M., Ronckers, C., Tissing, W.J.E., Vries, A.C.H. de, Kaspers, G.J.L., Bokenkamp, A., Veening, M.A., and Dutch LATER Study Grp
Subjects: Late effects, Hypertension, Ambulatory blood pressure monitoring, Nephrotoxicity, Childhood cancer survivor
Abstract: Purpose: To evaluate the prevalence of and risk factors for hypertension in child-hood cancer survivors (CCSs) who were treated with potentially nephrotoxic therapies. Methods: In the Dutch Childhood Cancer Survivor Study LATER cohort part 2 renal study, 1024 CCS >= 5 years after diagnosis, aged >= 18 years at study participation, treated between 1963 and 2001 with nephrectomy, abdominal radiotherapy, total body irradiation (TBI), cisplatin, carboplatin, ifosfamide, high-dose cyclophosphamide (>= 1 g/m(2) per single dose or >= 10 g/m(2) total) or haematopoietic stem cell transplantation participated and 500 controls from Lifelines. Hypertension was defined as blood pressure (BP) (mmHg) systolic >= 140 and/or diastolic >= 90 or receiving medication for diagnosed hypertension. At the study visit, the CKD-EPI 2012 equation including creatinine and cystatin C was used to estimate the glomerular filtration rate (GFR). Multivariable regression analyses were used. For ambulatory BP monitoring (ABPM), hypertension was defined as BP daytime: systolic >= 135 and/or diastolic >= 85, night time: systolic >= 120 and/or diastolic >= 70, 24-h: systolic >= 130 and/or diastolic >= 80. Outcomes were masked hypertension (MH), white coat hypertension and abnormal nocturnal dipping (aND). Results: Median age at cancer diagnosis was 4.7 years (interquartile range, IQR 2.4-9.2), at study 32.5 years (IQR 27.7-38.0) and follow-up 25.5 years (IQR 21.4-30.3). The prevalence of hypertension was comparable in CCS (16.3%) and controls (18.2%). In 12% of CCS and 17.8% of controls, hypertension was undiagnosed. A decreased GFR (< 60 ml/min/1.73 m(2)) was associated with hypertension in CCS (OR 3.4, 95% CI 1.4-8.5). Risk factors were abdominal radiotherapy >= 20 Gy and TBI. The ABPM-pilot study (n Z 77) showed 7.8% MH, 2.6% Conclusion: The prevalence of hypertension was comparable among CCS who were treated with potentially nephrotoxic therapies compared to controls, some of which were undiagnosed. Risk factors were abdominal radiotherapy >= 20 Gy and TBI. Hypertension and decreased GFR were associated with CCS. ABPM identified MH and a ND. (C) 2022 The Author(s). Published by Elsevier Ltd.
Published: 2022

43. Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study

Author: Kooijmans, E.C.M., Pal, H.J.H. van der, Pluijm, S.M.F., Heiden-van der Loo, M. van der, Kremer, L.C.M., Bresters, D., Dulmen-den Broeder, E. van, Heuvel-Eibrink, M.M. van den, Loonen, J.J., Louwerens, M., Neggers, S.J.C., Ronckers, C., Tissing, W.J.E., Vries, A.C.H. de, Kaspers, G.J.L., Bokenkamp, A., Veening, M.A., Dutch LATER Study Group, Pediatrics, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, Paediatrics, and Internal Medicine
Subjects: Cancer Research, childhood cancer survivor, ALPHA-1-MICROGLOBULIN, OUTCOMES, nephrotoxicity, tubular dysfunction, CHILDREN, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], CISPLATIN, All institutes and research themes of the Radboud University Medical Center, Oncology, SDG 3 - Good Health and Well-being, RISK-FACTORS, SARCOMA PATIENTS, HEALTH, HYPOMAGNESEMIA, IFOSFAMIDE-INDUCED NEPHROTOXICITY, ACUTE LYMPHOBLASTIC-LEUKEMIA
Abstract: Simple Summary We studied survivors of childhood cancer who received cancer treatment that might affect the kidneys and compared them to controls from the general population. We investigated if there was a difference in the occurrence of tubular dysfunction. The tubules are the part of the kidney responsible for reabsorption of needed substances to the blood and the removal of wastes. After around 25 years since their cancer diagnosis, we found that in general there were no differences between survivors and controls, but survivors more often had losses of small proteins in the urine. Yet, some survivors of childhood cancer were found to have an increased risk of tubular dysfunction. Namely, survivors treated with the chemotherapeutic agents ifosfamide, cisplatin or carboplatin. Therefore, these patients should be monitored during their follow-up. The aim of this nationwide cross-sectional cohort study was to determine the prevalence of and risk factors for tubular dysfunction in childhood cancer survivors (CCS). In the DCCSS-LATER 2 Renal study, 1024 CCS (>= 5 years after diagnosis), aged >= 18 years at study, treated between 1963 and 2001 with potentially nephrotoxic therapy (i.e., nephrectomy, abdominal radiotherapy, total body irradiation, cisplatin, carboplatin, ifosfamide, high-dose cyclophosphamide, or hematopoietic stem cell transplantation) participated, and 500 age- and sex-matched participants from Lifelines acted as controls. Tubular electrolyte loss was defined as low serum levels (magnesium < 0.7 mmol/L, phosphate < 0.7 mmol/L and potassium < 3.6 mmol/L) with increased renal excretion or supplementation. A alpha 1-microglobulin:creatinine ratio > 1.7 mg/mmol was considered as low-molecular weight proteinuria (LMWP). Multivariable risk analyses were performed. After median 25.5 years follow-up, overall prevalence of electrolyte losses in CCS (magnesium 5.6%, potassium 4.5%, phosphate 5.5%) was not higher compared to controls. LMWP was more prevalent (CCS 20.1% versus controls 0.4%). LMWP and magnesium loss were associated with glomerular dysfunction. Ifosfamide was associated with potassium loss, phosphate loss (with cumulative dose > 42 g/m(2)) and LMWP. Cisplatin was associated with magnesium loss and a cumulative dose > 500 mg/m(2) with potassium and phosphate loss. Carboplatin cumulative dose > 2800 mg/m(2) was associated with potassium loss. In conclusion, long-term tubular dysfunction is infrequent. Yet, ifosfamide, cisplatin and carboplatin are risk factors.
Published: 2022

44. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer

Author: Truin, W., Vugts, G., Roumen, R. M. H., Maaskant-Braat, A. J. G., Nieuwenhuijzen, G. A. P., van der Heiden-van der Loo, M., Tjan-Heijnen, V. C. G., and Voogd, A. C.
Published: 2016
Full Text: View/download PDF

45. The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands

Author: van der Heiden-van der Loo, M., Siesling, S., Wouters, M. W. J. M., van Dalen, T., Rutgers, E. J. T., and Peeters, P. H. M.
Published: 2015
Full Text: View/download PDF

46. 072 Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

Author: van der Kooi, A.L.L.F., primary, van Dijk, M., additional, Broer, L., additional, van den Berg, M., additional, Laven, J., additional, van Leeuwen, F., additional, Ronckers, C., additional, van der Heiden-van der Loo, M., additional, Hudson, M., additional, Byrne, J., additional, Pluijm, S., additional, Spix, C., additional, Kaatsch, P., additional, Kremer, L., additional, Yasui, Y., additional, Brooke, J., additional, Uitterlinden, A., additional, van den Heuvel-Eibrink, M., additional, and van Dulmen-den Broeder, E., additional
Published: 2022
Full Text: View/download PDF

47. Support needs of Dutch young adult childhood cancer survivors

Author: Erp, L., Maurice-Stam, H., Kremer, L., Tissing, W., Pal, H., Beek, L., Vries, A., Den Heuvel-Eibrink, M., Versluys, B., Heiden-Van Loo, M., Marloes van Gorp, Huizinga, G., Grootenhuis, M., Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, Child and Adolescent Psychiatry & Psychosocial Care, Pediatrics, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Subjects: Adult, Health Services Needs and Demand, Adolescent, Psychosocial support, Survivorship care, Social Support, Survivorship, Young Adult, Cancer Survivors, Oncology, SDG 3 - Good Health and Well-being, Neoplasms, Surveys and Questionnaires, Quality of Life, Humans, Original Article, Child, Childhood cancer, Needs, Young adults
Abstract: Background Studies about support needs of young adult childhood cancer survivors (YACCS) previously focused mainly on information needs. This study assessed support needs and associated factors (sociodemographic, medical, and psychosocial functioning) in Dutch YACCS. Methods YACCS (aged 18–30, diagnosed ≤ 18 years, time since diagnosis ≥ 5 years) cross-sectionally filled out a questionnaire regarding their need for various types of support (concrete information, personal counseling, and peer contact) in eight domains (physical consequences of childhood cancer, social-emotional consequences, relationships and sexuality, fertility, lifestyle, school and work, future perspective, insurance and mortgage), and questionnaires assessing health-related quality of life (PedsQL-YA), anxiety and depression (HADS), and fatigue (CIS-20R). Descriptive statistics were used to describe support needs. Linear regression was used to identify characteristics associated with support needs. Results One hundred fifty-one YACCS participated (response = 40%). Most YACCS reported a need for support in one or more domains (88.0%, N = 133). More than half of the participants reported a need for concrete information in the domains lifestyle, fertility, and physical consequences of childhood cancer and 25–50% in the domains insurance and mortgages, future perspective, and social-emotional consequences of childhood cancer. In the domains lifestyle and physical as well as emotional consequences of childhood cancer, 25–50% reported a need for counseling. Overall need for support was positively associated with middle (β = 0.26, p = 0.024) and high (β = 0.35, p = 0.014) compared to low educational attainment and (sub)clinical anxiety (β = 0.22, p = 0.017), and negatively associated with social functioning (β = − 0.37, p = 0.002) in multivariate analyses. Conclusion YACCS report the strongest need for support, for concrete information, in the domains lifestyle, fertility, and physical consequences of childhood cancer. Associated factors were mostly socioeconomic and psychosocial in nature. Psychosocial care should be an integral part of survivorship care for YACCS, with screening for psychosocial problems, information provision including associated emotional consequences and support if necessary (psycho-education) and tailored interventions, and adequate referrals to more specialized care if necessary.
Published: 2022

48. Increased health-related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho-oncology study

Author: Gorp, M. van, Erp, L.M.E. van, Maas, A, Kremer, L.C., Dulmen-den Broeder, E. van, Tissing, W.J., Loonen, J.J., Pal, H.J. van der, Vries, A.C.M. de, Heuvel-Eibrink, M.M. van den, Ronckers, C.M., Bresters, D., Louwerens, M., Heiden-van der Loo, M., Huizinga, G.A., Maurice-Stam, H., Grootenhuis, M.A., Gorp, M. van, Erp, L.M.E. van, Maas, A, Kremer, L.C., Dulmen-den Broeder, E. van, Tissing, W.J., Loonen, J.J., Pal, H.J. van der, Vries, A.C.M. de, Heuvel-Eibrink, M.M. van den, Ronckers, C.M., Bresters, D., Louwerens, M., Heiden-van der Loo, M., Huizinga, G.A., Maurice-Stam, H., and Grootenhuis, M.A.
Abstract: Item does not contain fulltext, BACKGROUND: The objective of this study was to compare the health-related quality of life (HRQOL) of Dutch adult male and female childhood cancer survivors (CCSs) to general population references and to study medical determinants. METHODS: CCSs from the Dutch Childhood Cancer Survivor Study LATER cohort (1963-2001) part 2, who were 18 years old or older (time since diagnosis ≥ 5 years), were invited to complete the TNO-AZL Questionnaire for Adult Health-Related Quality of Life. Domain scores and proportions of CCSs with impaired HRQOL (score < 25th percentile of the reference scores) were compared with references via Mann-Whitney U tests and logistic regression analyses corrected for age and sex (P < .004). Interactions of group with sex were included if they were significant (P < .05). Moreover, medical determinants were analyzed with multivariable logistic regression analyses. RESULTS: HRQOL scores for 1766 CCSs (mean age, 35.9 years [standard deviation, 9.4 years]; male, 51%; response rate, 71%) differed from references on most domains with small effect sizes. Both male and female CCSs were more often impaired in gross and fine motor functioning, cognitive functioning, sleep, and vitality with odds ratios (ORs) > 1.4. In addition, female CCSs were more often impaired in daily activities, pain, and sexuality (ORs, 1.4-1.9) and were less often aggressive (OR, 0.6). CCCs of central nervous system (CNS) tumors, bone tumors, and retinoblastoma and those with cranial, abdominopelvic, or lower extremity radiotherapy were at increased risk of impairment in 1 or more domains. CONCLUSIONS: Dutch adult CCSs, especially females, have impaired HRQOL in several domains; this is most pronounced in cognitive functioning. The vulnerabilities of subgroups at risk, such as CCSs of CNS tumors, were confirmed. Surveillance of HRQOL and multidisciplinary survivor care are recommended. LAY SUMMARY: The health-related quality of life in a Dutch nationwide cohort of 1766 survivors of chi
Published: 2022

49. Assessing fatigue in childhood cancer survivors: Psychometric properties of the Checklist Individual Strength and the Short Fatigue Questionnaire--a DCCSS LATER study

Author: Penson, A., Walraven, I., Bronkhorst, E.M., Grootenhuis, M.A., Tissing, W.J., Pal, H.J. van der, Vries, A.C.M. de, Heuvel-Eibrink, M.M. van den, Neggers, S., Versluys, B.A., Louwerens, M., Pluijm, S.M.F., Blijlevens, N.M., Heiden-van der Loo, M., Kremer, L.C., Dulmen-den Broeder, E. van, Knoop, H., Loonen, J.J., Penson, A., Walraven, I., Bronkhorst, E.M., Grootenhuis, M.A., Tissing, W.J., Pal, H.J. van der, Vries, A.C.M. de, Heuvel-Eibrink, M.M. van den, Neggers, S., Versluys, B.A., Louwerens, M., Pluijm, S.M.F., Blijlevens, N.M., Heiden-van der Loo, M., Kremer, L.C., Dulmen-den Broeder, E. van, Knoop, H., and Loonen, J.J.
Abstract: Item does not contain fulltext, BACKGROUND: Fatigue is often reported by patients with childhood cancer both during and after cancer treatment. Several instruments to measure fatigue exist, although none are specifically validated for use in childhood cancer survivors (CCS). The aim of the current study was to present norm values and psychometric properties of the Checklist Individual Strength (CIS) and Short Fatigue Questionnaire (SFQ) in a nationwide cohort of CCS. METHODS: In total, 2073 participants were included from the Dutch Childhood Cancer Survivor Study (DCCSS) LATER cohort. Normative data, construct validity, structural validity, and internal consistency were calculated for the CIS and SFQ. In addition, reliability and a cutoff score to indicate severe fatigue were determined for the SFQ. RESULTS: Correlations between CIS/SFQ and vitality measures asking about fatigue were high (>0.8). Correlations between CIS/SFQ and measures of different constructs (sleep, depressive emotions, and role functioning emotional) were moderate (0.4-0.6). Confirmatory factor analysis resulted in a four-factor solution for the CIS and a one-factor solution for the SFQ with Cronbach's alpha for each (sub)scale showing good to excellent values (>0.8). Test-retest reliability of the SFQ was adequate (Pearson's correlation = 0.88; ICC = 0.946; weighted Cohen's kappa item scores ranged 0.31-0.50) and a cut-off score of 18 showed good sensitivity and specificity scores (92.6% and 91.3%, respectively). CONCLUSION: The current study shows that the SFQ is a good instrument to screen for severe fatigue in CCS. The CIS can be used as a tool to assess the multiple fatigue dimensions in CCS.
Published: 2022

50. Prevalence and risk factors of cancer-related fatigue in childhood cancer survivors: A DCCSS LATER study

Author: Deuren, S van, Penson, A., Dulmen-den Broeder, E. van, Grootenhuis, M.A., Heiden-van der Loo, M., Bronkhorst, E.M., Blijlevens, N.M.A., Streefkerk, N., Teepen, J.C., Tissing, W.J., Pal, H.J. van der, Heuvel-Eibrink, M.M. van den, Versluys, B.A., Bresters, D., Leeuwen, F.E. van, Ronckers, C.M., Kremer, L.C., Knoop, H., Loonen, J.J., Deuren, S van, Penson, A., Dulmen-den Broeder, E. van, Grootenhuis, M.A., Heiden-van der Loo, M., Bronkhorst, E.M., Blijlevens, N.M.A., Streefkerk, N., Teepen, J.C., Tissing, W.J., Pal, H.J. van der, Heuvel-Eibrink, M.M. van den, Versluys, B.A., Bresters, D., Leeuwen, F.E. van, Ronckers, C.M., Kremer, L.C., Knoop, H., and Loonen, J.J.
Abstract: Item does not contain fulltext, BACKGROUND: Cancer-related fatigue is a debilitating late effect after treatment for childhood cancer. The prevalence of fatigue in childhood cancer survivors (CCSs) and associated factors for fatigue has varied widely in previous studies. Two important aspects of cancer-related fatigue, its severity and chronicity, are often not assessed. This study investigated the prevalence of, and risk factors for, severe chronic fatigue (CF) in a national cohort of Dutch CCSs. METHODS: In this study, 2810 CCSs (5-year survivors of all childhood malignancies diagnosed between 1963 and 2001 with a current age of 12-65 years) and 1040 sibling controls were included. CF was assessed with the Short Fatigue Questionnaire and was defined as a score ≥ 18 and persistence of fatigue for ≥6 months. Cancer- and treatment-related characteristics, current health problems, and demographic and lifestyle variables were assessed as potential risk factors for CF via multivariable logistic regression analyses. RESULTS: In adult CCSs and sibling controls (≥18 years old), the prevalence of CF was 26.1% and 14.1%, respectively (P < .001). In adolescent CCSs and sibling controls (<18 years old), the prevalence of CF was 10.9% and 3.2%, respectively. Female gender (odds ratio [OR], 2.13; 95% confidence interval [CI], 1.73-2.62), unemployment (OR, 2.18; 95% CI, 1.67-2.85), having 1 or more health problems (OR for 1-2, 1.48; 95% CI, 1.18-1.87; OR for >2, 2.20; 95% CI, 1.50-3.21), and a central nervous system diagnosis (OR, 1.74; 95% CI, 1.17-2.60) were significantly associated with CF in adult CCSs. CONCLUSIONS: This study shows that CCSs, regardless of their cancer diagnosis, report CF more often than sibling controls. This study provides new evidence for the prevalence of fatigue in CCSs.
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

764 results on '"Loo, M."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources